Bausch Health Companies Inc.
No SEC Form 4 filings for $BHC in the last 30 days.
Canadian stocks fell Tuesday after new U.S. “self-defense” strikes on Iran while ceasefire talks continued in Qatar. The S&P/TSX Composite ended at 34,653.87, down 0.51% (177.02 points). Utilities led gainers (+0.58%); IT and Consumer Staples fell. Market focus stayed on Strait of Hormuz reopening and U.S.-Iran negotiation signals.
Bausch Health (NYSE: BHC) shareholders held their Annual Meeting on May 19, 2026, where they approved the election of all nominated directors, including a new director, Eiry W. Roberts, M.D. They also provided non-binding advisory approval for the compensation of the Named Executive Officers and appointed PricewaterhouseCoopers LLP as the independent registered public accounting firm through the 2027 annual meeting, authorizing the board to set the auditors' remuneration. The company filed an 8-K report detailing the full voting results for each proposal.
Bausch Health Companies Inc. (NYSE:BHC) reported strong Q1 2026 results, marking 12 consecutive quarters of year-over-year revenue and adjusted EBITDA growth for Bausch Health excluding Bausch & Lomb. The company reaffirmed its full-year 2026 guidance, driven by robust performance from Salix and Solta, strategic investments in R&D and AI, and a disciplined approach to capital structure optimization despite missing EPS expectations. They are actively pursuing business development opportunities focused on late-stage or commercial-ready assets within their areas of expertise.
